Form 4: Director Derica Rice Increases BMY Equity Stake

Bristol-Myers Squibb director Derica W. Rice acquired 638.912 deferred share units as part of director compensation.

Summary

• Director Derica W. Rice acquired 638.912 deferred share units (DSUs) on March 31, 2026.
• The units were acquired at a price of $60.65 per share.
• Following this transaction, the director holds a total of 39,963.721 deferred share units.
• These units are settleable in common stock upon the director's departure from the board or at a previously specified future date.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation.

Positives

• Demonstrates alignment of interests between the director and shareholders through increased equity-linked holdings.

Negatives

• None identified; this is a standard director compensation transaction.

Risks

• Value of deferred share units is subject to the market performance of Bristol-Myers Squibb common stock.

Future Outlook

The deferred share units will convert to common stock upon the director's retirement from the board or at a pre-determined future date.

Industry Context

StockSavvy.ai notes that director equity acquisitions via deferred compensation plans are standard practice in the pharmaceutical industry to ensure long-term alignment with corporate performance.

Comparison to Industry Standards

• The transaction aligns with standard corporate governance practices for large-cap pharmaceutical companies like Pfizer or Merck, where directors are compensated with equity to maintain skin in the game.

Corporate Governance

Stakeholder Impact

• Minimal impact on shareholders; reflects standard director compensation.

Next Steps

• The director will continue to hold these units until the specified settlement conditions are met.

Key Dates

Keywords

BMY, Bristol-Myers Squibb, Insider Trading, Form 4, Director Compensation, Equity Ownership